Applied DNA Sciences Inc. (UDJ)
XMUN 
Summary
Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantzen - CFO James Hayward - Chairman & CEO Clay Shorrock - Chief Legal Officer & Executive Director, Business Development Judith Murrah - President & Secretary Conference Call Participants Eduardo Arce - H.C. Wainwright & Co Operator Good day, and welcome to the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results.
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.
Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.
Applied DNA Sciences Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | James A. Hayward Sc.D. CEO | XMUN Exchange | US03815U3005 ISIN |
| US Country | 46 Employees | - Last Dividend | 2 Jun 2025 Last Split | 15 Jul 2003 IPO Date |
Overview
Applied DNA Sciences, Inc. is a biotechnology firm that focuses on the development and commercialization of DNA-based technologies across a diverse range of industries globally, including the Americas, Europe, Asia, and beyond. With its foundations laid in 1983 and a rebranding from Datalink Systems, Inc. to its current name in 2002, the company has established its headquarters in Stony Brook, New York. It caters to various sectors through its innovative DNA-focused solutions, operating across three primary segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.
Products and Services
- Therapeutic DNA Production Services:
This segment centers on the development and commercialization of the LinearDNA platform. This groundbreaking technology facilitates the cell-free production of high-fidelity synthetic DNA sequences. These sequences are pivotal for nucleic acid-based therapeutics, offering a new frontier in the development of treatments and therapies.
- MDx Testing Services:
Applied DNA Sciences provides a comprehensive range of clinical molecular diagnostics (MDx) testing and clinical laboratory services. This includes specialized COVID-19 testing services under the safeCircle trademark, which encompasses test scheduling, sample collection, and automated results reporting tailored for higher education institutions, private clients, and businesses. Additionally, the segment provides polymerase chain reaction (PCR) services for the production and detection of DNA and RNA, alongside MDx test kits, related supplies, and isotopic analysis testing services.
- DNA Tagging and Security Products and Services:
This division offers SigNature Molecular Tags, a technology designed to authenticate goods within large and complex supply chains. These tags are applied to materials like cotton, nutraceuticals, and various other products to corroborate their authenticity and origin. Furthermore, the segment provides portable DNA readers (SigNify) and consumable reagent test kits that assist in the verification process. Another noteworthy product is fiberTyping, a PCR-based DNA detection system used to identify the naturally occurring DNA sequences in products. This technology ensures product provenance authentication and maximizes supply chain security.
Contact Information
